Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The overall probability of maintenance of complete molecular remission at 12 months after stopping dasatinib.
at 12 months
Nippon Medical School
Japan: Institutional Review Board